Key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028 LONDON, July 26, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received Issue Notification from the United…


Previous articleCOMPASS Pathways plc to announce second quarter 2022 financial results on 4 August 2022
Next articleBraxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth